Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism

Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism

Play episode

Audio Journal of Oncology Podcast
Audio Journal of Oncology Podcast
Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism
Loading
/

ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe and effective alternative strategy to standard treatment with the low molecular weight heparin dalteparin for avoiding recurrences of venous thromboembolism (VTE) in selected patients with cancer. The findings were reported at the 2017 meeting of the American Society of Hematology. Abstract 625: Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D Pilot Trial

“We found recurrence rates with dalteparin at six months were 11 per cent. With rivaroxaban the recurrence rates were four per cent,” said lead author Annie Young PhD, Professor of Nursing at Warwick Clinical Trials Unit in Warwick University Medical School’s Cancer Research Centre, UK. “Definitely we found that the rivaroxaban recurrence rates at six months were lower than dalteparin.”

READ MORE IN ONCOLOGY TIMES

More from this show

Sign up for AudioMedica.com news

* = required field
Speciality